Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome

por Rodriguez-Madoz, Juan Roberto, San Jose-Eneriz, Edurne, Rabal, Obdulia, Zapata-Linares, Natalia, Miranda, Estibaliz, Rodriguez, Saray, Porciuncula, Angelo, Vilas-Zornoza, Amaia, Garate, Leire, Segura, Victor, Guruceaga, Elizabeth, Agirre, Xabier, Oyarzabal, Julen, Prosper, Felipe
Publicado 2017

In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria

por Martinez-Turrillas, Rebeca, Martin-Mallo, Angel, Rodriguez-Diaz, Saray, Zapata-Linares, Natalia, Rodriguez-Marquez, Paula, San Martin-Uriz, Patxi, Vilas-Zornoza, Amaia, Calleja-Cervantes, María E., Salido, Eduardo, Prosper, Felipe, Rodriguez-Madoz, Juan R.
Publicado 2022

CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

por Zabaleta, Nerea, Barberia, Miren, Martin-Higueras, Cristina, Zapata-Linares, Natalia, Betancor, Isabel, Rodriguez, Saray, Martinez-Turrillas, Rebeca, Torella, Laura, Vales, Africa, Olagüe, Cristina, Vilas-Zornoza, Amaia, Castro-Labrador, Laura, Lara-Astiaso, David, Prosper, Felipe, Salido, Eduardo, Gonzalez-Aseguinolaza, Gloria, Rodriguez-Madoz, Juan R.
Publicado 2018